Validation Data Shows Rosetta's Array-based CUP Test Outperforms PCR-based Predecessor

Data from the study showed that Rosetta's array-based Mets 2 test has 88 percent concordance with clinical presentation and pathology, exceeding the accuracy of the PCR-based version of the test.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.